Table 1.
Total (n = 27) | High PMI (n = 13) | Low PMI (n = 14) | p value | |
---|---|---|---|---|
Age (years) | ||||
<65 | 13 (48.1%) | 7 (53.8%) | 6 (42.9%) | 0.568 |
≥65 | 14 (51.9%) | 6 (46.2%) | 8 (57.1%) | |
Gender | ||||
Female | 6 (22.2%) | 3 (23.1%) | 3 (21.4%) | 0.918 |
Male | 21 (77.8%) | 10 (76.9%) | 11 (78.6%) | |
Creatinine clearance (mL/min.) | ||||
<60 | 12 (44.4%) | 6 (46.2%) | 6 (42.9%) | 0.8632 |
≥60 | 15 (55.6%) | 7 (53.8%) | 8 (57.1%) | |
Cystectomy or nephroureterectomy | ||||
Yes | 16 (59.3%) | 10 (76.9%) | 6 (42.9%) | 0.0719 |
No | 11 (40.7%) | 3 (23.1%) | 8 (57.1%) | |
Response after 2 courses of GN therapy | ||||
CR and PR | 13 (48.1%) | 10 (76.9%) | 3 (21.4%) | 0.0719 |
SD and PD | 14 (51.9%) | 6 (46.2%) | 8 (57.1%) | |
Adverse effects (grade ≥ 3) | ||||
Neutropenia | 25 (92.6%) | 12 (92.3%) | 13 (92.9%) | 0.9566 |
Thrombocytopenia | 17 (63.0%) | 8 (61.5%) | 9 (64.3%) | 0.6802 |
Appetite loss or nausea | 1 (3.7%) | 1 (7.7%) | 0 (0%) | 0.2903 |